| Literature DB >> 30108153 |
Jingya Lyu1, Hitomi Imachi1, Kensaku Fukunaga1, Seisuke Sato1, Tomohiro Ibata1, Toshihiro Kobayashi1, Tao Dong1, Takuo Yoshimoto1, Kazuko Yonezaki1, Hiromi Nagata1, Hisakazu Iwama2, Koji Murao3.
Abstract
In pancreatic β cells, ABCA1, a 254 kDa membrane protein, affects cholesterol homeostasis and insulin secretion. Angiotensin II, as the main effector of the renin-angiotensin system, decreases glucose-stimulated insulin secretion (GSIS). We examined the effect of angiotensin II on ABCA1 expression in primary pancreatic islets and INS-1 cells. Angiotensin II decreased ABCA1 protein and mRNA; angiotensin II type 1 receptor (AT1R) blockade rescued this ABCA1 repression. In parallel, angiotensin II suppressed the promoter activity of ABCA1, an effect that was abrogated by PD98095, a specific inhibitor of MAPK kinase (MEK). LXR enhanced ABCA1 promoter activity, and angiotensin II decreased the nuclear abundance of LXR protein. On a chromatin immunoprecipitation assay, LXR mediated the transcription of ABCA1 by directly binding to its promoter. Mutation of the LXR binding site on the ABCA1 promoter cancelled the effect of angiotensin II. Furthermore, angiotensin II induced cholesterol accumulation and impaired GSIS; inhibition of AT1R or MEK pathway reversed these effects. In summary, our study showed that angiotensin II suppressed ABCA1 expression in pancreatic islets and INS-1 cells, indicating that angiotensin II may influence GSIS by regulating ABCA1 expression. Additional research may address therapeutic needs in diseases such as diabetes mellitus.Entities:
Keywords: MAPK kinase/ERK1/2; lipotoxicity; liver X receptor
Mesh:
Substances:
Year: 2018 PMID: 30108153 PMCID: PMC6168299 DOI: 10.1194/jlr.M085886
Source DB: PubMed Journal: J Lipid Res ISSN: 0022-2275 Impact factor: 5.922